Recent Transactions

13-May-25
Pending
Undisclosed
Australia flag
Target: 

Seagrass Boutique Hospitality Group

Japan flag
Acquiror: 
Colowide Co., Ltd

Advising Seagrass Boutique Hospitality Group (“Seagrass”), a Crescent Capital Partners portfolio company, on its sale to Tokyo Stock Exchange listed Colowide Co., Ltd. Seagrass is one of Australia and the UAE’s largest and most successful premium steak-based restaurant groups

08-May-25
Undisclosed
United Kingdom flag
Target: 

German Doner Kebab ("GDK")

United Kingdom flag
Acquiror: 
True

Advised Hero Brands on the strategic investment in GDK by True. GDK is a leading Middle Eastern quick-service restaurant brand, with over 145 franchised locations in the UK and 170 globally, including the US, Canada, Sweden and the Middle East

05-May-25
Pending
~$10 billion
United States flag
Target: 

Skechers U.S.A., Inc.

United States flag
Acquiror: 
3G Capital

Advising Skechers, the third largest footwear company in the world, on its sale to 3G Capital

28-Mar-25
Pending
$100 million
United Kingdom flag
Target: 

UK High Street business of WH Smith PLC

United Kingdom flag
Acquiror: 
Modella Capital

Advising WH Smith PLC, one of the UK’s leading retailers, on the sale of its UK High Street business

11-Feb-25
$320 million (AUD value)
Australia flag
Target: 

Pacific Smiles Group

Australia flag
Acquiror: 
Genesis Capital

Advised Pacific Smiles Group Limited, one of Australia’s leading and fastest growing dental service organisations, on its response to multiple private equity proposals and ultimate sale to Genesis Capital by way of off-market takeover

04-Feb-25
Pending
$1.1 billion
United States flag
Target: 

PRISM Vision Group

United States flag
Acquiror: 
McKesson Corporation

Advising PRISM Vision Group, a leading medical eye care services company, on its majority stake sale to McKesson Corporation, a diversified healthcare services and distribution leader

24-Dec-24
Undisclosed
Israel flag
Target: 

Ex-US rights to branded narcolepsy treatments, Provigil® (modafinil) and Nuvigil® (armodafinil)

Germany flag
Acquiror: 
Neuraxpharm Group

Advised Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company, on the acquisition of the ex-US rights to Provigil® (modafinil) and Nuvigil® (armodafinil) from Teva Pharmaceuticals Industries Ltd. (“Teva”)

14-Nov-24
$263 million
France flag
Target: 

Robertet SA

France flag
Acquiror: 
Fonds Stratégique de Participations and Peugeot Invest SA

Advising Fonds Stratégique de Participations and Peugeot Invest SA, on the acquisition of a 14% stake for €250 million in Robertet SA, world leader in natural products, from DSM-Firmenich AG 

13-Nov-24
Pending
Undisclosed
Germany flag
Target: 

Centogene GmbH

Italy flag
Acquiror: 
Charme Capital Partners

Advising Charme Capital Partners, a European mid-market private equity fund, on the acquisition of Centogene GmbH, a leading provider of  pharmaceutical solutions and diagnostic tests for rare diseases

01-Jul-24
Undisclosed
United States flag
Target: 

Medical Review Institute of America

United States flag
Acquiror: 
Parthenon Capital

Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital

26-Jun-24
Pending
$630 million
Euro flag
Target: 

Haleon plc’s Nicotine Replacement Therapy Business (ex-US)

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories

20-Jun-24
Pending
$1.8 billion
United States flag
Target: 

CP Kelco

United Kingdom flag
Acquiror: 
Tate & Lyle

Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation

08-May-24
$800 million
United States flag
Target: 

U.S. Acute Care Solutions

flag not available

Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes

01-May-24
Undisclosed
United States flag
Target: 

Functional Formularies

France flag
Acquiror: 
Danone

Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital

09-Apr-24
Undisclosed
United States flag
Target: 

Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.

Korea flag
Acquiror: 
SAE-A Trading

Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

16-Nov-23
~$400 million
United States flag
Target: 

Sonoma-Cutrer Vineyards (Brown-Forman)

United States flag
Acquiror: 
The Duckhorn Portfolio

Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio

18-Sep-23
Pending
Undisclosed
France flag
Target: 

Central nervous system (CNS) portfolio from Sanofi

United Kingdom flag
Acquiror: 
Pharmanovia

Advising Pharmanovia, a UK based global lifecycle management healthcare company, on the acquisition of a global central nervous system portfolio from Sanofi, the France based innovative global healthcare company

10-Aug-23
Undisclosed
United Kingdom flag
Target: 

Clinigen Ltd’s portfolio of Established Medicines

United Kingdom flag
Acquiror: 
CNX Therapeutics

Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners

08-Aug-23
Pending
Undisclosed
Spain flag
Target: 

Farmalider Group

Spain flag
Acquiror: 
MCH

Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH

20-Jun-23
Pending
$595 million
United Kingdom flag
Target: 

Lookers Plc

Canada flag
Acquiror: 
Alpha Auto Group

Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group

01-Jun-23
Pending
Undisclosed
United States flag
Target: 

Interest in Joint Venture with CarepathRx Health System Solutions

United States flag
Acquiror: 
The Cigna Group

Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary

26-Apr-23
Pending
$127 million
Australia flag
Target: 

Marley Spoon business combination with 468 SPAC II

Germany flag
Acquiror: 
468 SPAC II SE

Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities

25-Apr-23
Pending
Undisclosed
United Kingdom flag
Target: 

Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®

United Kingdom flag
Acquiror: 
Advanz Pharma (UK)

Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company

20-Mar-23
Pending
Undisclosed
Target: 

Clinigen Ltd’s Lamda Laboratories

Germany flag
Acquiror: 
Adragos Pharma

Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO

Pages

show all